Symbols

BIIB

Biogen·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 4

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Below Expectations

Revenue Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BIIB

Biogen Inc.

One of the world's first global biotech companies and develops treatments for neurodegenerative, autoimmune and heatologic disorders

Industry

Biological Technology

Established Date

Listing Date

09/20/1991

Exchange

NASDAQ Stock Exchange

Full-time Employees

7,500

Fiscal Year Ends

12-31

Website

www.biogen.com

Security Type

Common stock

Office address

225 Binney Street, Cambridge, MA 02142

Business

Manufacture and sale of medicines for the treatment of multiple sclerosis

Introduction

Biogen Inc., founded in California in 1985 as IDEC Pharmaceuticals, Inc., was re-registered as a Delaware corporation in 1997. In 2003, Biogen, Inc., was acquired and the company name was changed to Biogen Idec Inc. The company is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative therapies for people with serious and complex diseases. The company has an extensive multiple sclerosis (MS) drug portfolio, launched the first approved drug for spinal muscular atrophy (SMA), co-developed a treatment that addresses the defining pathology of Alzheimer's disease, and launched the first approved therapy for the genetic cause of amyotrophic lateral sclerosis (ALS). Biogen also markets the first and only drug approved for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. Its R&D efforts focus on neurology, specialized immunology and rare diseases, and are supported by internal projects, collaborations and acquisitions. The company commercializes biologics and biosimilars and maintains strategic partnerships with leading pharmaceutical companies to advance its product portfolio.

Company Financials

EPS

BIIB has released its 2025 Q4 earnings. EPS was reported at 1.99, versus the expected 1.61, beating expectations. The chart below visualizes how BIIB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIIB has released its 2025 Q4 earnings report, with revenue of 2.28B, reflecting a YoY change of -7.14%, and net profit of -48.90M, showing a YoY change of -118.34%. The Sankey diagram below clearly presents BIIB's revenue sources and cost distribution.